NDC properties for "Tlando 112.5 MG Oral Capsule" (RxCUI 2599060)
About this data
The tables show NDC propoerties for Tlando 112.5 MG Oral Capsule with the RxCUI 2599060
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product
Details for Tlando 112.5 MG Oral Capsule (RxCUI 2599060)
MMSL_CODE | BD38640 |
---|---|
NDA | NDA208088 |
RxCUI | 2599060 |
SPL_SET_ID | 479b55bd-2023-486a-8922-3b1de48b935c |
SPL_SET_ID | 4b0b92e9-6d3c-a0e5-e1c7-342999f72580 |
Prescribable Synonym | TLANDO 112.5 MG Oral Capsule |
RXNAV_STR | Tlando 112.5 MG Oral Capsule |
RxNorm Name | testosterone undecanoate 112.5 MG Oral Capsule [Tlando] |
RxNorm Synonym | Tlando 112.5 MG Oral Capsule |
Related queries | Interactions (for RxCUI 2599060) |
NDC Properties
NDC Item 54436011220
NDC 9 | 54436-112 |
---|---|
NDC 10 | 54436-112-20 |
NDC Item | 54436011220 |
Packaging | 120 CAPSULE, LIQUID FILLED in 1 BOTTLE, PLASTIC (54436-112-20) |
COLORTEXT | white(opaque body and a grey opaque cap, banded with a colorless band) |
Color | C48325 __ |
DCSA | CIII |
FDA SPL set id | 754257 |
Imprint code | 112 |
Labeler | Antares Pharma, Inc. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time low | 2022-04-15 |
Marketing status | ACTIVE |
NDA | NDA208088 |
Score | 1 |
Shapetext | CAPSULE |
Shape | C48336 |
Size | 21 mm |
Related queries | Properties for NDC 9 54436-112 |
NDC Item 74676011202
NDC 9 | 74676-0112 |
---|---|
NDC 10 | 74676-0112-2 |
NDC Item | 74676011202 |
Packaging | 120 CAPSULE, LIQUID FILLED in 1 BOTTLE, PLASTIC (74676-0112-2) |
COLORTEXT | white(opaque body and a grey opaque cap, banded with a colorless band) |
Color | C48325 __ |
DCSA | CIII |
FDA SPL set id | 772291 |
Imprint code | 112 |
Labeler | Verity Pharmaceuticals Inc. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time low | 2022-04-15 |
Marketing status | ACTIVE |
NDA | NDA208088 |
Score | 1 |
Shapetext | CAPSULE |
Shape | C48336 |
Size | 21 mm |
Related queries | Properties for NDC 9 74676-0112 |
NDC Item 54436011220
NDC 9 | 54436-112 |
---|---|
NDC 10 | 54436-112-20 |
NDC Item | 54436011220 |
Packaging | 120 CAPSULE, LIQUID FILLED in 1 BOTTLE, PLASTIC (54436-112-20) |
COLORTEXT | white(opaque body and a grey opaque cap, banded with a colorless band) |
Color | C48325 __ |
DCSA | CIII |
FDA SPL set id | 754257 |
Imprint code | 112 |
Labeler | Antares Pharma, Inc. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time low | 2022-04-15 |
Marketing status | ACTIVE |
NDA | NDA208088 |
Score | 1 |
Shapetext | CAPSULE |
Shape | C48336 |
Size | 21 mm |
Related queries | Properties for NDC 9 54436-112 |
NDC Item 74676011202
NDC 9 | 74676-0112 |
---|---|
NDC 10 | 74676-0112-2 |
NDC Item | 74676011202 |
Packaging | 120 CAPSULE, LIQUID FILLED in 1 BOTTLE, PLASTIC (74676-0112-2) |
COLORTEXT | white(opaque body and a grey opaque cap, banded with a colorless band) |
Color | C48325 __ |
DCSA | CIII |
FDA SPL set id | 772291 |
Imprint code | 112 |
Labeler | Verity Pharmaceuticals Inc. |
Label type | HUMAN PRESCRIPTION DRUG |
Marketing category | NDA |
Marketing effective time low | 2022-04-15 |
Marketing status | ACTIVE |
NDA | NDA208088 |
Score | 1 |
Shapetext | CAPSULE |
Shape | C48336 |
Size | 21 mm |
Related queries | Properties for NDC 9 74676-0112 |